Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin D & prostate cancer

This article was originally published in The Tan Sheet

Executive Summary

Researchers planning Phase III trial on high-dose vitamin D as adjunct to chemotherapy agent docetaxel for treatment of advanced stage prostate cancer. In Phase II investigation, Tomasz Beer, MD, Oregon Health & Science University, et al., found 30 of 37 (81%) hormone-refractory prostate cancer patients treated with .5 mcg calcitriol (active form of vitamin D) plus docetaxel for six weeks saw 50% reduction in prostate-specific antigen levels; eight of 15 men with measurable disease experienced significant reduction in tumor size. In earlier trials testing only docetaxel, approximately 42% of patients had the same PSA response, Beer et al. say. Results were reported at American Society of Clinical Oncology annual meeting in Orlando, Fla. May 18...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel